Danish and English researchers have completed the first phase, ie study on healthy people who Science Radio first reported on, Björn Herman, assistant professor of clinical microbiology, examines chlamydia at Uppsala Academic Hospital and says the study is important because it is the first phase of a chlamydia vaccine study.
"This is a breakthrough," he tells SVT News.
He points out that there are many more years to go when there may be a vaccine on the market, but a study of this vaccine candidate showed two things:
– Partly that it has shown no harmful side effects, it is important when driving. The other important thing is that the immune system has started in a way that a person can expect to protect against chlamydia infection, says Björn Hermann.
130 million are infected each year
Chlamydia is the most common sexually transmitted disease in the world. Each year, about 130 million people worldwide are infected according to the World Health Organization, and 30,000-35,000 of them are Swedes.
Chlamydia can be treated with antibiotics, but the infection does not always cause symptoms, making it difficult to stop the spread of the infection. The infection can lead to serious complications, especially in women who may suffer from fallopian tubes, ectopic pregnancy and infertility.
"These are important reasons for vaccination," says Björn Herman.